Merger Outlook For 2004: Pfizer Fortunes Key To More M&A, Analysts Say
A demonstration by Pfizer of renewed vigor following the acquisition of Pharmacia could kick off another round of merger & acquisition activity in 2004, securities analysts predict
You may also be interested in...
Pfizer's $1.3 bil. acquisition of Esperion will reunite the Lipitor research team and give Pfizer two more chances to develop a novel mechanism anti-atherosclerotic agent
GlaxoSmithKline is relying primarily on line extensions and supplemental indications to fill its nearer-term pipeline before the effect of a revamped R&D effort kicks in
Merck appears to be distancing itself from a blanket "no merger" policy by offering a formula under which it would consider a large-scale transaction